PMID: 8477092Jan 1, 1993Paper

Serotonergic mechanisms are involved in the hemostatic action of erythropoietin in uremic patients

International Journal of Clinical & Laboratory Research
J MalyszkoW Buczko


Recombinant human erythropoietin was administered to 12 patients with end-stage renal failure on long-term hemodialysis. They responded to the therapy with a shortening of the prolonged bleeding time, starting from the 1st week of therapy, before a significant increase in hemoglobin concentration was achieved. We also observed an increase in the activity of tissue plasminogen activator and a decrease in the activity of its inhibitor. There were no changes in platelet count but a significant increase in blood and platelet serotonin concentration was found. The shortening of the prolonged bleeding time before the correction of the anemia correlated with the rise in blood and platelet serotonin concentration during erythropoietin therapy. We suggest the possible involvement of an serotonergic mechanism in the hemostatic action of recombinant human erythropoietin.


Nov 1, 1977·Thrombosis Research·R L Kinlough-RathboneJ F Mustard
Apr 1, 1964·Clinica Chimica Acta; International Journal of Clinical Chemistry·G W ASHCROFTE J MACDOUGALL

❮ Previous
Next ❯


Jan 1, 1996·International Journal of Clinical & Laboratory Research·J S MalyszkoM Mysliwiec
Jun 15, 2006·Wiener klinische Wochenschrift·Walter H Hörl
Sep 9, 2010·Arthritis Care & Research·Charles Sèbiyo BatchoJean-Louis Thonnard

❮ Previous
Next ❯

Related Concepts

Related Feeds


Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.